xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

299

Orlandi et al.

(Continues)

No synergistic effect between INCS and antibiotics

Milder cases benefited from the INCS while more severe cases didnot

SNOT-20, QoL Higher dose INCS had clinically significant improvement in SNOT-20

better than all other groups

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Bachert 422 2007 2 RCT(n = 981) Mometasone 200 μ gBID

INCS BID was significantly

Improvement in Total Symptom Severity Scoreby > 4points

Symptom severity and resolution

Amoxicillin 500 mg TID + placebo spray daily (n = 60) Budesonide 200 μ gdaily +

placebo antibiotic (n = 64) Placebo antibiotic + placebo spray (n = 63)

Williamson 434 2007 2 RCT(n = 240) Amoxicillin 500 mg TID + budesonide 200 μ gdaily (n = 53)

Meltzer 420 2005 2 RCT(n = 981) Mometasone 200 μ gBID

Mometasone 200 μ gdaily

Mometasone 200 μ gdaily

Amoxicillin 500 mg TID (n = 251) + placebo spray Placebo spray + placebo antibiotics (n = 252)

Amoxicillin 500 mg TID (n = 251) + placebo spray Placebo spray + placebo antibiotic (n = 252)

(n = 243) + placebo antibiotic

(n = 243) + placebo antibiotic

(n = 235) + placebo antibiotic

(n = 235) + placebo antibiotic

TABLE VII-11 (Continued)